A Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenously Administered Andexanet After Dosing to Steady-State With Oral Betrixaban in Healthy Subjects
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2018
At a glance
- Drugs Andexanet alfa (Primary) ; Betrixaban (Primary)
- Indications Haemorrhage
- Focus Therapeutic Use
- Sponsors Portola Pharmaceuticals
- 06 Jun 2018 Planned End Date changed from 1 May 2018 to 1 Sep 2018.
- 06 Jun 2018 Planned primary completion date changed from 1 May 2018 to 1 Sep 2018.
- 09 Nov 2017 New trial record